Pieris Pharmaceuticals, Inc. (PIRS)

$0.171731

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Pieris Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 20.05M → 1.29M (in $), with an average decrease of 48.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -10.75M → -4.58M (in $), with an average increase of 134.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.5% return, outperforming this stock by 125.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 251.9% return, outperforming this stock by 344.2%

Performance

  • $0.17
    $0.18
    $0.17
    downward going graph

    0.0%

    Downside

    Day's Volatility :5.5%

    Upside

    5.5%

    downward going graph
  • $0.14
    $1.01
    $0.17
    downward going graph

    19.94%

    Downside

    52 Weeks Volatility :86.52%

    Upside

    83.17%

    downward going graph

Returns

PeriodPieris Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
0.84%
-1.1%
0.0%
6 Months
-39.45%
6.7%
0.0%
1 Year
-76.8%
2.4%
-1.5%
3 Years
-92.26%
17.2%
-20.6%

Highlights

Market Capitalization
17.8M
Book Value
$0.31
Earnings Per Share (EPS)
-0.34
PEG Ratio
0.0
Wall Street Target Price
7.0
Profit Margin
-59.25%
Operating Margin TTM
15.81%
Return On Assets TTM
-17.25%
Return On Equity TTM
-84.68%
Revenue TTM
47.4M
Revenue Per Share TTM
0.56
Quarterly Revenue Growth YOY
263.5%
Gross Profit TTM
-27.1M
EBITDA
-19.2M
Diluted Eps TTM
-0.34
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.35
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
-0.12
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Pieris Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
7
7
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 3976.14%

Current $0.17
Target $7.00

Company Financials

FY18Y/Y Change
Revenue
29.1M
↑ 15.14%
Net Income
-26.8M
↑ 51.61%
Net Profit Margin
-91.93%
↓ 22.11%
FY19Y/Y Change
Revenue
46.3M
↑ 59.03%
Net Income
-23.8M
↓ 11.21%
Net Profit Margin
-51.33%
↑ 40.6%
FY20Y/Y Change
Revenue
29.3M
↓ 36.64%
Net Income
-37.2M
↑ 56.72%
Net Profit Margin
-126.97%
↓ 75.64%
FY21Y/Y Change
Revenue
31.4M
↑ 7.14%
Net Income
-43.4M
↑ 16.48%
Net Profit Margin
-138.03%
↓ 11.06%
FY22Y/Y Change
Revenue
25.9M
↓ 17.56%
Net Income
-31.3M
↓ 27.93%
Net Profit Margin
-120.66%
↑ 17.37%
FY23Y/Y Change
Revenue
42.8M
↑ 65.28%
Net Income
-24.5M
↓ 21.47%
Net Profit Margin
-57.33%
↑ 63.33%
Q3 FY22Q/Q Change
Revenue
5.4M
↑ 45.21%
Net Income
-8.5M
↓ 9.23%
Net Profit Margin
-158.86%
↑ 95.28%
Q4 FY22Q/Q Change
Revenue
5.8M
↑ 8.86%
Net Income
-8.1M
↓ 5.33%
Net Profit Margin
-138.15%
↑ 20.71%
Q1 FY23Q/Q Change
Revenue
1.9M
↓ 66.88%
Net Income
-12.3M
↑ 52.45%
Net Profit Margin
-635.95%
↓ 497.8%
Q2 FY23Q/Q Change
Revenue
20.1M
↑ 935.9%
Net Income
4.0M
↓ 132.29%
Net Profit Margin
19.83%
↑ 655.78%
Q3 FY23Q/Q Change
Revenue
19.5M
↓ 2.67%
Net Income
-10.8M
↓ 370.42%
Net Profit Margin
-55.08%
↓ 74.91%
Q4 FY23Q/Q Change
Revenue
1.3M
↓ 93.35%
Net Income
-4.6M
↓ 57.37%
Net Profit Margin
-352.89%
↓ 297.81%
FY18Y/Y Change
Total Assets
141.3M
↑ 36.07%
Total Liabilities
101.4M
↑ 9.8%
FY19Y/Y Change
Total Assets
141.1M
↓ 0.17%
Total Liabilities
89.7M
↓ 11.5%
FY20Y/Y Change
Total Assets
105.0M
↓ 25.58%
Total Liabilities
74.0M
↓ 17.56%
FY21Y/Y Change
Total Assets
153.6M
↑ 46.23%
Total Liabilities
102.8M
↑ 38.96%
FY22Y/Y Change
Total Assets
95.5M
↓ 37.82%
Total Liabilities
67.6M
↓ 34.28%
FY23Y/Y Change
Total Assets
38.7M
↓ 59.49%
Total Liabilities
11.9M
↓ 82.35%
Q3 FY22Q/Q Change
Total Assets
99.2M
↓ 13.25%
Total Liabilities
63.4M
↓ 9.36%
Q4 FY22Q/Q Change
Total Assets
95.5M
↓ 3.7%
Total Liabilities
67.6M
↑ 6.57%
Q1 FY23Q/Q Change
Total Assets
82.3M
↓ 13.86%
Total Liabilities
66.8M
↓ 1.13%
Q2 FY23Q/Q Change
Total Assets
87.5M
↑ 6.43%
Total Liabilities
47.0M
↓ 29.57%
Q3 FY23Q/Q Change
Total Assets
59.4M
↓ 32.18%
Total Liabilities
28.9M
↓ 38.64%
Q4 FY23Q/Q Change
Total Assets
38.7M
↓ 34.86%
Total Liabilities
11.9M
↓ 58.7%
FY18Y/Y Change
Operating Cash Flow
-1.1M
↓ 102.14%
Investing Cash Flow
-8.9M
↓ 80.65%
Financing Cash Flow
48.5M
↑ 1086.09%
FY19Y/Y Change
Operating Cash Flow
-52.5M
↑ 4821.86%
Investing Cash Flow
9.8M
↓ 210.85%
Financing Cash Flow
32.2M
↓ 33.69%
FY20Y/Y Change
Operating Cash Flow
-45.9M
↓ 12.52%
Investing Cash Flow
39.2M
↑ 298.58%
Financing Cash Flow
10.1M
↓ 68.55%
FY21Y/Y Change
Operating Cash Flow
-7.7M
↓ 83.31%
Investing Cash Flow
-949.0K
↓ 102.42%
Financing Cash Flow
59.1M
↑ 484.55%
Q3 FY22Q/Q Change
Operating Cash Flow
-8.8M
↓ 43.65%
Investing Cash Flow
5.5M
↓ 150.35%
Financing Cash Flow
282.0K
↑ 0.36%
Q4 FY22Q/Q Change
Operating Cash Flow
-12.9M
↑ 47.33%
Investing Cash Flow
-1.4M
↓ 124.97%
Financing Cash Flow
93.0K
↓ 67.02%
Q1 FY23Q/Q Change
Operating Cash Flow
-11.0M
↓ 14.98%
Investing Cash Flow
11.9M
↓ 971.38%
Financing Cash Flow
19.8M
↑ 21169.89%
Q2 FY23Q/Q Change
Operating Cash Flow
-13.4M
↑ 22.14%
Investing Cash Flow
-1.4M
↓ 111.48%
Financing Cash Flow
19.8M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Pieris Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
-1.47%
-39.45%
-76.8%
-92.26%
-94.48%
Moderna, Inc.
Moderna, Inc.
-1.29%
6.96%
-34.5%
-29.77%
306.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.29%
7.75%
8.95%
89.65%
140.93%
Novo Nordisk A/s
Novo Nordisk A/s
-6.73%
21.9%
48.54%
251.87%
394.48%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.03%
6.89%
18.96%
83.64%
117.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
NA
NA
0.0
-0.35
-0.85
-0.17
NA
0.31
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.28
26.28
1.51
44.87
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.38
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.64
28.64
0.54
16.78
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
Buy
$17.8M
-94.48%
NA
-59.25%
Moderna, Inc.
Moderna, Inc.
Buy
$41.0B
306.89%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$100.2B
140.93%
26.28
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$565.1B
394.48%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.8B
117.3%
28.64
36.68%

Institutional Holdings

  • Bvf Inc

    20.85%
  • Renaissance Technologies Corp

    1.08%
  • BlackRock Inc

    1.05%
  • Acadian Asset Management LLC

    0.97%
  • Vanguard Group Inc

    0.92%
  • Geode Capital Management, LLC

    0.77%

Corporate Announcements

  • Pieris Pharmaceuticals, Inc. Earnings

    Pieris Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche

Organization
Pieris Pharmaceuticals, Inc.
Employees
127
CEO
Mr. Stephen S. Yoder J.D.
Industry
Health Technology

FAQs